Clavix Tablets (Clopidogrel Hydrogen Sulfate)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start with a loading dose of 300 mg of this medicine once daily on the day treatment is initiated, followed by a maintenance dose of 75 mg orally once daily. In this case, aspirin 75 ～ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. In this case, aspirin 75 ～ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate liver disease and a bleeding diathesis is limited. This medicine may be administered with or without food.

This medication prevents blood platelets from aggregating to inhibit thrombus formation. During the use of this medication, the risk of bleeding may increase, so if symptoms of bleeding or easy bruising occur, consult a physician immediately. Patients genetically deficient in the specific enzyme (CYP2C19) may experience reduced effectiveness of this medication, and alternatives should be considered in such cases. Taking this medication with certain drugs may alter the concentration of the active ingredient, so inform your doctor or pharmacist if you are using other medications. Patients with severe bleeding, severely impaired liver or kidney function, breastfeeding women, and those with lactose intolerance should not take this medication. Patients scheduled for surgery should discontinue this medication 5-7 days before the procedure, and it should be administered with caution in bleeding prone conditions. Caution is advised as the risk of bleeding may increase when used concomitantly with other antiplatelet agents, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), or selective serotonin reuptake inhibitors (SSRIs). Safety in children and pregnant women has not been adequately established, so its use is generally not recommended except in special cases. Elderly patients or those with low body weight have a higher risk of bleeding, thus require more caution during treatment. In case of overdose, bleeding time may be prolonged, and immediate medical treatment is necessary as there is no specific antidote available. This medication should be kept out of reach of children and should not be transferred to another container.

• Hemorrhage
• gastrointestinal bleeding
• bleeding requiring hospitalization
• purpura
• contusion
• hematoma
• epistaxis
• hematuria
• ocular hemorrhage
• intracranial hemorrhage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to ensure the medication’s effectiveness.

Appearance

Pink round film-coated tablets

Package unit

For domestic use - 30 tablets/bottle, For domestic use - 100 tablets/bottle, For export - 30 tablets/box [(10 tablets/PTP × 3)]